Inhaler Carbon Footprint – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on improving respiratory outcomes while reducing the carbon emissions from inhalers and has data at SICBL, ICB and Commissioning Region level.

NHS England Aims: To improve patient outcomes and reduce carbon footprint of inhalers.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Additional resources

The RDTC has also produced an Inhaler Carbon Impact Assessment Tool

Frequency

Quarterly

Data period

January 2021 to December 2023

Polypharmacy – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on addressing problematic polypharmacy and has data at SICBL, ICB and Commissioning Region level.

NHS England Aims: Identify and review patients with problematic polypharmacy. Support cultural and behavioural changes.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Cardiovascular – MO opportunities

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report has data at SICBL, ICB and Commissioning Region level and focuses on the cardiovascular MO opportunities:

  • Identifying patients with atrial fibrillation and using best value direct-acting oral anticoagulants
  • Identifying patients with hypertension and starting antihypertensives where appropriate
  • Optimising lipid management for cardiovascular disease prevention

NHS England Aims:

  • To increase the diagnosis of AF and anti-coagulate with the best value DOAC where clinically appropriate.
  • Identify patients with hypertension and start antihypertensives when appropriate.
  • Increase the proportion of patients with CVD prescribed a statin and 2nd line therapies where required, to optimise lipid management. Reduction in CVD deaths, and hospital admissions for MI and stroke.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Antidepressants – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on addressing inappropriate antidepressant prescribing and has data at SICBL, ICB and Commissioning Region level.

NHS England Aim: Reduce inappropriate long-term prescribing and associated spend on antidepressants.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Sodium Valproate – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on improving valproate safety and has data at SICBL, ICB and Commissioning Region level.

NHS England Aim:

  • Prescribing valproate only in line with the guidance issued by MHRA and CHM.
  • Reduction in babies born with birth defects and neurodevelopmental disorders.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Opioids – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on reducing opioid use in chronic non-cancer pain and has data at SICBL, ICB and Commissioning Region level.

NHS England Aim: Reduce the number of patients prescribed an opioid for use in chronic non-cancer pain and reduce the number of patients receiving an oral morphine equivalent of ≥120mg/day.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Blood Glucose Test Strips – MO opportunities

Overview

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report focuses on the appropriate prescribing and supply of blood glucose and ketone meters and testing strips and has data at SICBL, ICB and Commissioning Region level.

In 2023, NHS England published Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets. This details the recommended meters, strips and lancets, that following evaluation have been determined to have the highest quality and be most cost effective.

NHS England Aim: to utilise the best value blood glucose and ketone meters, and testing strips.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data period

January 2021 to December 2023

Low priority prescribing – MO opportunities

Overview

This SICBL report is a locality level subsection of the Medicines Optimisation Opportunities Dashboard. It looks at prescribing trends for items and cost, for those items which should not be routinely prescribed in primary care, now termed Low priority prescribing. The NHSE ‘Items which should not be routinely prescribed in primary care’ guidance was originally published in Nov 2017, but has since been updated in 2023. The items and targets presented here reflect the latest guidance update, although a baseline of 2017 is additionally included to demonstrate progress already achieved in this area. ICB, regional and England level data is also included.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data Period

January 2021 to December 2023

Growth Contrast Tool

Overview

The growth contrast tool is intended to help ICBs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove the effect of system-wide changes (e.g. price increases, patent expiries, discontinuations, shortages, implementation of national guidance, etc.) & bring local effects into focus.

Data Period

April 2023 to December 2023

Frequency

Quarterly

Shared care protocol – azathioprine and mercaptopurine for adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.1

Last updated: 8th March 2024.